Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.2950 (6.42%) ($6.2950 - $6.2950) on Tue. Jul. 19, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.93% (three month average) | RSI | 82 | Latest Price | $6.2950(6.42%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 16.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(76%) ARKG(74%) ARKK(66%) IBB(66%) IWC(62%) | Factors Impacting TGTX price | TGTX will decline at least -3.465% in a week (0% probabilities). UUP(-37%) TBT(-19%) USO(-8%) XLE(-1%) EDOC(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.465% (StdDev 6.93%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $6.14(2.52%) | 10 Day Moving Average | $5.81(8.35%) | 20 Day Moving Average | $5.16(22%) | To recent high | -20.4% | To recent low | 68.5% | Market Cap | $797m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |